Your browser doesn't support javascript.
loading
Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior.
Pan, Lisa A; Martin, Petra; Zimmer, Thomas; Segreti, Anna Maria; Kassiff, Sivan; McKain, Brian W; Baca, Cynthia A; Rengasamy, Manivel; Hyland, Keith; Walano, Nicolette; Steinfeld, Robert; Hughes, Marion; Dobrowolski, Steven K; Pasquino, Michele; Diler, Rasim; Perel, James; Finegold, David N; Peters, David G; Naviaux, Robert K; Brent, David A; Vockley, Jerry.
Afiliação
  • Pan LA; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Martin P; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Zimmer T; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Segreti AM; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Kassiff S; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • McKain BW; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Baca CA; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Rengasamy M; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Hyland K; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Walano N; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Steinfeld R; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Hughes M; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Dobrowolski SK; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Pasquino M; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Diler R; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Perel J; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Finegold DN; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Peters DG; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Naviaux RK; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Brent DA; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
  • Vockley J; From the Departments of Psychiatry, Pediatrics, Human Genetics, Pathology, and Obstetrics and Gynecology, University of Pittsburgh, School of Medicine, Pittsburgh; Medical Neurogenetics Laboratory, Atlanta; the Department of Pediatrics, University Medical Center Göttingen, Göttingen, Germany; and th
Am J Psychiatry ; 174(1): 42-50, 2017 Jan 01.
Article em En | MEDLINE | ID: mdl-27523499
ABSTRACT

OBJECTIVE:

Treatment-refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. At least 15% of cases of major depressive disorder remain refractory to treatment. The authors previously identified a young adult with treatment-refractory depression and multiple suicide attempts with an associated severe deficiency of CSF tetrahydrobiopterin, a critical cofactor for monoamine neurotransmitter synthesis. Treatment with sapropterin, a tetrahydrobiopterin analogue, led to dramatic and long-lasting remission of depression. This sentinel case led the authors to hypothesize that the incidence of metabolic abnormalities contributing to treatment-refractory depression is underrecognized.

METHOD:

The authors conducted a case-control, targeted, metabolomic evaluation of 33 adolescent and young adult patients with well-characterized histories of treatment-refractory depression (at least three maximum-dose, adequate-duration medication treatments), and 16 healthy comparison subjects. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry and high-performance liquid chromatography electrospray ionization tandem mass spectrometry.

RESULTS:

CSF metabolite abnormalities were identified in 21 of the 33 participants with treatment-refractory depression. Cerebral folate deficiency (N=12) was most common, with normal serum folate levels and low CSF 5-methyltetrahydrofolate (5-MTHF) levels. All patients with cerebral folate deficiency, including one with low CSF levels of 5-MTHF and tetrahydrobiopterin intermediates, showed improvement in depression symptom inventories after treatment with folinic acid; the patient with low tetrahydrobiopterin also received sapropterin. None of the healthy comparison subjects had a metabolite abnormality.

CONCLUSIONS:

Examination of metabolic disorders in treatment-refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities remains to be determined.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tentativa de Suicídio / Transtorno Depressivo Resistente a Tratamento / Ácido Fólico / Deficiência de Ácido Fólico Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tentativa de Suicídio / Transtorno Depressivo Resistente a Tratamento / Ácido Fólico / Deficiência de Ácido Fólico Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article